Medical Device | November 02, 2021
Thermo Fisher Scientific realigns product portfolio
Consolidation of the Acros Organics, Alfa Aesar and Maybridge brands to one single brand, Thermo Scientific
Consolidation of the Acros Organics, Alfa Aesar and Maybridge brands to one single brand, Thermo Scientific
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
_256_384.jpg)
Both parties are expected to invest a total of US $ 1 million to establish the brand
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
This funding will help the start-up consolidate its position as a one-stop destination for pet parents as they holistically reimagine the entire pet care ecosystem
Cipla has reported consolidated financial results for the period ended September 30, 2021
Filing marks first protein-based vaccine submitted to MHRA for authorization
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
